
Within the next two weeks, biotech firm Zealand Pharma might get hold of its first own approval. The US Food and Drug Administration (FDA) will present its evaluation on the firm's rescue pen for treating acute low blood sugar in diabetes patients before March 27.
If an approval ensues, the rapidly growing company will be met with a new test of strength:
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app